Exciting Ventures: S2S China Unveils 2026 Finalists Ready to Impress Global Investors

S2S China Announces 2026 Finalists

In a bold step towards fostering innovation in the biotech sector, the inaugural S2S China Symposium has revealed the finalists for its 2026 program. This symposium, co-hosted by RA Capital Management and Qiming Venture Partners, represents a significant collaboration aimed at connecting top academic researchers with leading investors in the biotech industry.

The S2S China initiative is an extension of the renowned Science2Startup program, which was established in 2018 by F-Prime Capital, SV Health Investors, and Atlas Venture. The purpose of S2S is to bridge the gap between cutting-edge academic research and the practicalities of the biotech investment world. Over the years, it has successfully linked talented researchers with influential stakeholders, including biotech investors, pharmaceutical scouts, and corporate executives.

From a highly competitive applicant pool, ten standout teams were chosen to showcase their innovative projects. These teams will undergo a comprehensive mentorship program designed to help refine their pitches and strengthen their business frameworks. The culmination of their efforts will occur at an on-site event at Westlake University on October 15, where these teams will present their ideas to distinguished international venture capitalists.

The selection process for this year's finalists was highly selective. Following multiple rounds of rigorous evaluations by an advisory panel comprised of seasoned biopharma investors, the competition narrowed from a large field of entries down to approximately 20 semifinalist teams, ultimately selecting ten exceptional teams to advance to the final pitch event.

To enhance their engagement with investors and solidify their project frameworks, the finalists will participate in a mentorship program prior to the event. During this period, they will collaborate with the S2S China Symposium advisory board—a group of experienced industry professionals—to refine their scientific proposals, sharpen their commercial narratives, and optimize their presentation materials. This preparation is critical for raising the maturity level of their projects and establishing a solid groundwork in advance of their pitches.

The S2S China Symposium garners support from several eminent figures in academia and the global life sciences investment community, including Shi Yigong, President of Westlake University, Kan Chen from Qiming Venture Partners, and Josh Resnick from RA Capital Management. Their involvement is a testament to the symposium's role as a crucial link between China’s robust academic research landscape and the broader global biotech investment network.

This year's event is set to unite a range of globally recognized institutions and biopharma leaders, creating a dynamic ecosystem that nurtures the innovative spirit of the industry. The strong backing of leading corporate sponsors—such as Platinum Sponsors Goodwin, Eli Lilly, and Biocytogen, along with Gold Sponsor Johnson & Johnson and Silver Sponsor Sanofi—demonstrates a collective commitment to advancing early-stage therapeutics development originating from China onto the world stage.

Highlights of the Sponsors
1. Goodwin: This global law firm operates at the crossroads of capital and innovation, providing legal counsel to innovators and investors in various sectors including healthcare, life sciences, and technology.
2. Eli Lilly: Headquartered in Indianapolis, this pharmaceutical leader focuses on creating cutting-edge medicines that improve lives worldwide.
3. Biocytogen: Specializing in next-generation antibody therapeutics, this biotechnology company is recognized for its wide-ranging portfolio of novel drug candidates.
4. Johnson & Johnson: A global healthcare heavyweight, Johnson & Johnson is dedicated to addressing major health challenges through innovative science.
5. Sanofi: A biopharmaceutical powerhouse, Sanofi focuses on delivering scientific breakthroughs across multiple therapeutic areas.

The S2S China Symposium stands as a vibrant platform promoting innovation and fostering strategic relationships that catalyze the growth of biotech ventures. As the selected teams prepare for their pivotal pitch event, excitement grows regarding the potential impact of their innovations on the global market, illuminating China's role as an emerging leader in the biomedical sector.

For additional details about the symposium and participating teams, visit s2schina.com.